3 clinics shown
Restpadd operates a mental health clinic on Walnut Street in Red Bluff, serving patients in northern California's Tehama County. The practice provides outpatient psychiatric services, though specific treatment modalities such as TMS, esketamine, or ketamine therapy are not detailed in available information. Patients seeking specialized procedural treatments should contact the clinic directly to confirm current service offerings and insurance acceptance.
Tehama County Outpatient Clinic operates a general medical facility on Walnut Street in Red Bluff, serving residents of rural Northern California. The clinic provides outpatient medical services under Tehama County Health Services, though specific psychiatric or behavioral health treatment offerings are not detailed in available listings. Patients seeking specialized mental health treatments such as TMS therapy or esketamine should contact the clinic directly to confirm whether those services are available or if referrals to regional providers are offered.
Victor Community Support Services operates a mental health facility on Belle Mill Road in Red Bluff, serving adults in Northern California's Tehama County. The practice provides outpatient psychiatric services and community-based mental health support. Specific treatment modalities such as TMS, ketamine, or esketamine are not listed in available information; prospective patients should contact the clinic to confirm which services and interventions are currently offered.
Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.
Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.
Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.
The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.
Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.